Programs DISTINGUISHED FACULTY

DISTINGUISHED FACULTY:

John Allinson, FIBMS, Laboratory Director, Veeda Clinical Research

Stewart Bates, Ph.D., Director, Stevenage Core Technologies Group, Discovery
Technology Group, GlaxoSmithKline

John C. Bloom, V.M.D., Ph.D., Executive Director, Diagnostic & Experimental Medicine, Eli Lilly & Co.

Michael E. Burczynski, Ph.D., Associate Director, Biomarker Lab, Clinical Translational Medicine, Wyeth Pharmaceuticals

C. Thomas Caskey, M.D., F.A.C.P., Director & Chief Executive Officer, The Brown Foundation Institute of Molecular Medicine and Genetics, The University of Texas, Health Science Center at Houston

Maryellen de Mars, Ph.D., Director, Clinical Biomarkers, The Critical Path Institute

Viswanath Devanarayan, Ph.D., Director, Statistics, Biomarker Research, Abbott Laboratories

Nicholas C. Dracopoli, Ph.D., Vice President, Biomarkers, Centocor Research & Development, Johnson & Johnson

Iman El-Hariry, M.D., Ph.D., Group Director, Oncology MDC, GlaxoSmithKline Research & Development

Robert E. Epstein, M.D., M.S., Senior Vice President, Medical & Analytical Affairs; Chief Medical Officer, Medco Health Solutions, Inc.

Giora Feuerstein, M.D., Assistant Vice President & Head, Discovery Translational Medicine, Wyeth Research

Paul J. Fielder, Ph.D.,  Senior Director & Senior Scientist, Early Development Pharmacokinetics, Pharmacodynamic and Bioanalytical Sciences, Genentech, Inc.    

Mark Fidock, Ph.D., Head, Biochemical and Molecular BioMarkers, Experimental Biological Sciences, Pfizer Limited

Dorothee Foernzler, Ph.D., Biomarker-Experimental Medicine Leader, F. Hoffmann-La Roche AG

Alberto Gutierrez, Ph.D., Deputy Director, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD), U.S. Food
and Drug Administration

Yiwu He, Ph.D., Senior Program Officer, Global Health Discovery, Bill & Melinda Gates Foundation

Phil Hewitt, Ph.D., Head, Molecular Toxicology, Institute of Toxicology, Merck KGaA

Darren Hodgson, Ph.D., Biomics Advisor, Oncology Therapy Area, AstraZeneca

Martina Kaufmann, Ph.D., Biomarker Project Leader, Early Clinical Development Oncology, Novartis Pharma AG

Geert Kolvenbag, M.D., Ph.D., Global Product Vice President, Oncology, AstraZeneca Pharmaceuticals, Inc.

Chetan Lathia, Ph.D., Director, Global Clinical Pharmacology, Bayer Corp.

Kwan Lee, Ph.D., Senior Director, Department of Biostatistics and Data Management, GlaxoSmithKline

Francois Legay, Ph.D., Global Head, Marker Localization & Assays, Novartis Pharma AG

Lawrence J. Lesko, Ph.D., F.C.P., Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Klaus Lindpaintner, M.D., M.P.H., Head, Medical Genomics & Vice President, Research, F. Hoffmann-La Roche AG

Helen M. Moore, Ph.D., Director, Biospecimen Research Network, National Cancer Institute, National Institutes of Health

Patrick Y. Mueller, Ph.D., Project Leader, Safety Assessment, Novartis Pharma AG

Matthew R. Nelson, Ph.D., Senior Scientific Investigator, Statistical Genetics Development, GlaxoSmithKline

Scott D. Patterson, Ph.D., Executive Director, Medical Sciences, Amgen, Inc.

Christoph Petry, Ph.D., Head, Molecular Research Germany, Siemens Healthcare Diagnostics Products GmbH

Wendy Sanhai, Ph.D., Senior Scientific Advisor, Office of the Commissioner, U.S. Food and Drug Administration

Yaping Shou, M.D., Ph.D., Director, Oncology Biomarkers and Imaging, Novartis Pharmaceuticals     

Brian B. Spear, Ph.D., Director, Scientific Affairs, Global Pharmaceutical Research and Development, Abbott Labs

Linda C. Surh, M.D., Ph.D., FRCPC, Director, CEDD Global Regulatory Affairs, Neurosciences and Pharmacogenetics, GlaxoSmithKline, UK

Ole Vesterqvist, Ph.D., Senior Director, Biomarker Lab & Outsourcing, Clinical Translational Medicine, Wyeth Research

Xinkang Wang, Ph.D., Head, Imaging Biomarker Group, Discovery Translational Medicine, Wyeth Research

Jeffrey Waring, Ph.D., Associate Research Fellow & Group Leader, Cellular & Molecular Toxicology, Abbott Labs

David Wholley, Director, Biomarkers Consortium, Foundation for the National Institutes of Health

Hans Winkler, Ph.D., Senior Director & Global Head, Oncology Biomarkers, Pharmaceutical Research & Development, Johnson & Johnson